Beamtree Holdings Ltd · ASX:BMT
Beamtree — Pacific Knowledge Systems — Investor Presentation (August 2020)
29 slides from Beamtree's investor presentation, Aug 28, 2020
Slide 1: Pacific Knowledge Systems Investor Presentation Financial Year 2020
For personal use only Pacific Knowledge Systems Investor Presentation Financial Year 2020
Slide 2: Agenda
Agenda Company Overview For personal use only Who We Are What We Do PKS Strategic Advantages FY20 Highlights Market and Customers Market Opportunities PKS Global Footprint Growth, Current Products and Opportunities Growth Strategy PKS Enhanced Offering Product Development Through Integration PKS Fut
Slide 3: Overview
Overview “Intelligent systems for better health outcomes” For personal use only PKS is a healthcare technology business that provides proprietary subscription- PKS Pro Forma P&L 2020 based and advisory business focused solutions for better health outcomes through Pro forma FY20 P&L ($000) its suite
Slide 4: Outlook FY21
Outlook FY21 “Intelligent systems for better health outcomes” For personal use only 1 Target revenue growth in excess of 20% 2 Significant enhancements to the product portfolio 3 Cross sell products between PKS ands Pavilion Health 4 Continued high recurring revenue (+70%) 5 Maintain high Operationa
Slide 5: Company Overview
For personal use only Overview Company
Slide 6: Who we are
Who we are “Intelligent systems for better health outcomes” For personal use only PKS is an Australian Healthcare Technology company that works with health Over 170+ customers globally Direct Revenue of 86% organisations around the Ongoing growth in overseas markets world to: • better capture, manag
Slide 7: Who we are
Who we are “Intelligent systems for better health outcomes” For personal use only Pressures on Healthcare Organisations PKS’ products and services have a broad range of applications across the healthcare industry: Financial Pressures • Provide Clinical Decision Support, enabling better Patient Volum
Slide 8: PKS Strategic Advantages
PKS Strategic Advantages PKS has been significantly strengthen by the acquisition of Pavilion For personal use only Combine complementary products to provide a broader offering to customers 1 • Offers complementary health information solutions to the Healthcare Industry • Utilises their existing cus
Slide 9: FY20 Highlights
FY20 Highlights The acquisition and successful integration of Pavilion, numerous renewals, new customers For personal use only Victorian Government Renewal New Executive ACT Pathology Renewal Team SA Pathology Signs PKS Initial Public Offer New Healthscope Combined Strategy Initiated NZ Renewal FY19
Slide 10: FY20 Highlights in detail
FY20 Highlights in detail The acquisition and successful integration of Pavilion, numerous renewals, new customers For personal use only Acquisition and integration of Pavilion Health Renewal agreement with Victorian Government Pavilion Health is an Australian cloud-based software This renewal agree
Slide 11: Market and Customers
For personal use only Customers Market and
Slide 12: Market Opportunity
Market Opportunity Where PKS Products & Services operate in global health-tech sector For personal use only PKS represents an opportunity to participate in the large and fast growing global Health-Tech • Products & Advisory Services $10 tn Global Healthcare solutions market, providing a range of pro
Slide 13: PKS Global Footprint of 170+ Customers
PKS Global Footprint of 170+ Customers PKS has reinforced its Australian client base and expanded into Ireland, Singapore and the Middle East For personal use only Partner A Europe USA Middle East Asia Australia South Africa NZ
Slide 14: Growth: Current Products and Opportunities
For personal use only Growth: Current Products and Opportunities
Slide 15: PKS Enhanced Offerings
PKS Enhanced Offerings For personal use only RippleDown® Auditor picq® RippleDown Auditor is a knowledge-based system that allows Auditing tool that assesses every record clinically coded multiple departments to audit data entered into healthcare for data quality. information systems in real-time. M
Slide 16: Growth Strategy
Growth Strategy PKS key strategies to drive growth in revenue and earnings For personal use only Following the successful Growth in existing markets integration of Pavilion, PKS has a Cross-sell and up-sell the existing products for RippleDown® and PICQ®/RISQTM customers. strong Sales Strategy and e
Slide 17: Product development through integration
Product development through integration Using the best technology to enhance and ready products for the future: For personal use only Use RippleDown® within PICQ®/RISQTM Use RippleDown technology directly within PICQ®/RISQTM as a replacement or enhancement to Synergies in Development Processes the e
Slide 18: PKS Future Product Roadmap
PKS Future Product Roadmap The future roadmap for PKS is focused on: For personal use only RippleDown® Enhance user interface & migrate to Extend into other pathology Extend use beyond Auditor streams (e.g. molecular cloud-based version pathology diagnostics) Expert Application Consolidate into one
Slide 19: PKS Future Opportunities
PKS Future Opportunities The future roadmap for PKS is focused on: For personal use only Computer-Aided Coding (billing). End-to-end coding management platform providing a single user interface via a Coding Module. Data and Data-analytics. Automates the coding process to reduce the labour cost of co
Slide 20: FY20 Financials
For personal use only FY20 Financials
Slide 21: Financials – P&L audited and pro forma
Financials – P&L audited and pro forma For personal use only ` FY2020 FY2020 FY2019 Proforma Statement of Profit and Loss ($000) (Proforma Group) (Audited) (Proforma) Operating Revenue: Recurring Software Licenses 5,562 3,810 3,309 Project, Consulting and Implementation 1,685 315 542 Government Gran
Slide 22: FY20 Revenue Breakdown
FY20 Revenue Breakdown PKS is focused on increasing direct revenue and expanding its global customer base For personal use only Global Sales Recurring Recurring Revenue in FY20 was Partner Direct - 75% of total sales. 14% Revenue of 75% Pathology 38% This has continued an upward trend in recurring r
Slide 23: Financials – Balance Sheet Breakdown
Financials – Balance Sheet Breakdown For personal use only PKS holdings continues to retain a strong cash Net Cash balance of $4.20 million balance of $4.20 million. This cash balance will support PKS’ growth strategy and product roadmap. Net Asset increase of $9 million Net Cash from operating acti
Slide 24: The Team and Shareholders
For personal use only The Team and Shareholders
Slide 25: PKS Executive Team
PKS Executive Team For personal use only Mike Ron van Hill der Pluijm Non-Executive Doug Henry Paul O’Connor Mike Pollitt Dr. Lindsay Peters Chief Executive Officer Chief MD and CEOOperations Officer Chief Commercial Officer Chief Product Officer Chief Technology Officer Chairman ▪ Ron van der Pluij
Slide 26: Board of Directors
Board of Directors For personal use only Mike Hill Ron van der Pluijm Andrew Gray Paul Williams Stephen Borness Brad Lancken Non-Executive Chairman MD and CEO Non-Executive Director Non-Executive Director Chris Smith Non-Executive Director Non-Executive Director ▪ Former partner of Ernst & Director
Slide 27: Shareholder Structure
Shareholder Structure For personal use only PKS strong financial year is reflected in its increase in share price during ASX:PKS - Share Pricing FY20. 0.30 The acquisition of Pavilion was favourably received by the market 0.25 allowing PKS to continue its accelerated growth journey. 0.20 0.15 PKS ha
Slide 28: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about PKS Holdings Limited (PKS) and is current at the date of the presentation, 28 August 2020. For personal use only All Pavilion Health Australia Pty Ltd (Pavilion) Financials are based on Pavilion
Slide 29: For further information
For further For personal use only information Ron van der Pluijm Mike Hill CEO PKS Holdings Chairman PKS Holdings Phone: 0427 498 615 Phone: 0421 056 691
Pacific Knowledge Systems — Investor Presentation (August 2020) on 6ix